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Adverse cardiac remodeling followingmyocardial infarction (MI) remains a significant causeof congestiveheart fail-
ure. Additional and novel strategies that improve our ability to predict, diagnose, or treat remodeling are needed.
Numerous groups have explored single and multiple biomarker strategies to identify diagnostic prognosticators of
remodeling progression, which will improve our ability to promptly and accurately identify high-risk individuals.
The identification of better clinical indicators should further lead tomore effective prediction and timely treatment.
Matrix metalloproteinase (MMP-9) is one potential biomarker for cardiac remodeling, as demonstrated by both
animal models and clinical studies. In animal MImodels, MMP-9 expression significantly increases and is linked
with inflammation, diabetic microvascular complications, extracellular matrix degradation and synthesis, and
cardiac dysfunction. Clinical studies have also established a relationship between MMP-9 and post-MI remodel-
ing and mortality, making MMP-9 a viable candidate to add to the multiple biomarker list. By definition, a prox-
imal biomarker shows a close relationship with its target disease, whereas a distal biomarker exhibits
non-targeted disease modifying outcomes. In this review, we explore the ability of MMP-9 to serve as a proximal
biomarker for cardiac remodeling and a distal biomarker for inflammation. We summarize the current molecular
basis and clinical platform that allow us to include MMP-9 as a biomarker in both categories.
© 2013 Elsevier Inc.
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1. Introduction
Despite significant advancements in risk prediction, cardiovascular
disease remains a leading cause of death (Roger et al., 2011).Myocardial
infarction (MI) is one of the most highly prevalent cardiovascular
diseases, with over 1.2 million Americans being diagnosed with MI an-
nually. While short-term one month survival rates have dramatically
improved over the last 30 years, post-MI remodeling progressing to
heart failure remains a significant clinical issue. This issue is further
fueled by increased incidences of obesity, metabolic syndrome, and dia-
betes, all ofwhich exacerbate the cardiac remodeling response (Horwich
& Fonarow, 2010; Roger et al., 2011). Because heart failure is associated
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with substantial morbidity andmortality, as well as an impaired quality
of life (Goldberg et al., 2007), improved methods to identify at
risk patients before they develop heart failure is a primary goal. MI
modulates several biological pathways that converge in the remod-
eling response, which is characterized by changes in left ventricle
(LV) size, shape, and function (Lindsey & Zamilpa, 2012; Pfeffer &
Braunwald, 1990).
Several plasma or serumproteins have been characterized in the con-
text of heart failure, and these are broadly classified as markers of LV re-
modeling. Included in the list are extracellular matrix (ECM) markers —
collagen, matrix metalloproteinases (MMPs), and tissue inhibitors of
metalloproteinases (TIMPs); inflammatorymarkers— C-reactive protein
(CRP), tumor necrosis factor α, and interleukins (IL)— 1, 6, and 18; oxi-
dative stress markers— homocysteine and myeloperoxidase; neurohor-
monal activation markers — renin, angiotensin II, and aldosterone;
myocyte injurymarkers— cardiac specific troponins and creatine kinase;
and myocyte stress markers — brain natriuretic peptide (BNP) and
N-terminal pro-BNP (Braunwald, 2008; Fertin et al., 2012; Maisel et al.,
2002; Opdenakker et al., 2001; Tang et al., 2007; Velagaleti et al.,
2010). To date, a myriad of candidate circulating biomarkers have been
examined as LV remodeling or heart failure predictors, but the use of
one biomarker to accurately assess disease diagnosis, stage, and progres-
sion has not been successful and is not expected to be fruitful. To illus-
trate this point, while average BNP levels are higher in patients with
heart failure, individual levels vary from 100 to 1400 ng/ml. BNP shows
a wide spectrum of values and does not stratify with heart failure
stage, and BNP responses to heart failure treatments are influenced by
comorbidities such as renal failure (Lang &Mancini, 2007). This variation
is so large that BNP cannot effectively separate patientswith andwithout
heart failure (Maisel et al., 2002). A more successful approach will likely
be to use a multi-marker panel profiling scheme to assess markers dur-
ing each category (diagnosis, stage, progression) from the initial MI
event to progressive remodeling to the development of heart failure. Of
the analytes that have been examined, MMPs provide several candidate
biomarkers.
MMPs are zinc-dependent endopeptidases that cleave several
ECM proteins and as such modulate outcome of various physiological
and pathological processes including MI, atherosclerosis and conges-
tive heart failure. In addition to structural ECM components, MMP
substrates also include a multitude of ligand and receptor substrates
such as cytokines, chemokines, growth factors, and adhesion mole-
cules that alter cellular migration, adhesion, and activation. MMPs,
therefore, exert a strong influence on cardiac remodeling through
multiple mechanisms (Lindsey, 2004; Lindsey & Zamilpa, 2012;
Sternlicht & Werb, 2001). MMPs are endogenously inhibited by the
tissue inhibitors of metalloproteinases (TIMPs), a family comprised
of four members, TIMP-1, -2, -3, and -4. Pre-clinical and clinical stud-
ies in the post-MI setting indicate that MMP-1, -2, -3, -7, -8, -9, -12,
-13, and -14 and TIMP-1, -2 -3, and -4 are relevant to MI and LV re-
modeling (Hansson et al., 2011; Lindsey & Zamilpa, 2012; Rohde et
al., 1999; Yarbrough et al., 2003; Zamilpa & Lindsey, 2010).
For the most part, MMPs are secreted from the cell as proMMPs and
are activated extracellularly by tissue or plasma proteinases. The first
step in activation involves cleavage of a part of the propeptide, and
complete activation occurs with removal of the entire propeptide by
the MMP intermediate or by other active MMPs (Nagase et al., 2006).
MMPs can also be activated in vitro by treatment with organomercurial
compounds, urea, SH reagents, and chaotropic agents, which chemically
perturb the proMMP to alter its structure and permit activity without
loss of the 10 kD pro-domain. Other exogenousMMP activators include
oxidants such as HOCl and ONOO−, which activate proMMPs by
reacting with the cysteine in the propeptide. This activation process
can also take place in vivo, under inflammatory conditions (Gu et al.,
2002; Peppin &Weiss, 1986). On the other hand themajor endogenous
MMP inhibitor in serum is α2-macroglobulin and in tissue are the
TIMPs (Sorokin, 2010).
In 2001, an NIH working group standardized the definition of a bio-
marker as any characteristic that can be objectively evaluated as an in-
dicator of a normal biological process, a pathological process, or a
pharmacological responses to therapeutic intervention (Biomarkers
Definitions Working Group, 2001; Vasan, 2006). The American Heart
Association released a scientific statement focused on the importance
for developing biomarkers to enhance diagnostic methods and provide
surrogate measures of treatment efficacy (Balagopal et al., 2011;
Fortmann et al., 2004; Hlatky et al., 2009; Richards, 2009; Smith et al.,
2004; Vasan, 2006). Because no single biomarkerwill likely provide suf-
ficient information to predict disease progression, the next step is to
identify the combination of markers that improve risk prediction be-
yond what is currently available. A combination biomarker strategy
can also be used strategically tomake go or no-go decisions thatwill ac-
celerate drug discovery (Krishna & Wagner, 2010). An essential bio-
marker, by definition, would modulate both the target response as
well as distal events related to disease outcome (Krishna & Wagner,
2010; Krishna et al., 2008).
In this review, we provide rationale for using MMP-9 as a bio-
marker. We will discuss its effectiveness as a proximal biomarker
for cardiac remodeling (one that shows a close relationship with its
target disease) and a distal biomarker for inflammation (one that ex-
hibits non-targeted disease modifying outcomes). We provide a logic
model by which to evaluate the inclusion of MMP-9 as a candidate
marker for post-MI remodeling that may also serve as a template to
evaluate other candidate markers.
2. Methods of review
We searched PubMed for all papers that included MMP-9, which
totaled over 13,000 papers. We then focused the search by articles
published in the past 1, 2, 3, 5, or 10 years. Subsequently, we added
inflammation, cardiac remodeling, cardiovascular, myocyte, fibroblast,
neutrophils, or leukocytes to the MMP-9 keyword search (each term
was searched individually withMMP-9). We included all clinical reports,
review articles, journal articles, clinical trial reports, meta-analysis stud-
ies, randomized controlled trials, and original research manuscripts that
were published in English. The numbers of manuscripts with these key
words are shown in Fig. 1.
3. Pre-clinical and clinical studies:
MMP-9-mediated proximal effects (Fig. 2)
3.1. Post-MI LV healing phases
Following MI, both the infarcted region as well as the remote
non-infarcted zone undergo cardiac remodeling as a part of the
wound healing response (Pfeffer & Braunwald, 1990). The LV healing
response can be divided into two overlapping phases, the inflamma-
tory and reparative phases. The first phase, the inflammatory phase,
is characterized by the robust release of inflammatory mediators
and degradation of ECM that occurs in the setting of myocyte necro-
sis. During the inflammatory phase, cardiomyocyte death triggers
the rapid activation of the complement system, which induces free
radical production and activates the toll-like receptor-mediated path-
way. The second phase, the reparative phase, is characterized by fi-
broblast proliferation and release of fibrosis-promoting cytokines
that contribute positively to scar formation, with the net result
being increased ECM synthesis and deposition (Frantz et al., 2009).
The inflammatory and fibrotic pathways share several components.
For example, both pathways involve activation of nuclear factor kappa-B
(NF-κB) in infiltrating and resident myocardial cells to stimulate the ex-
pression of cytokines, chemokines, growth factors, and adhesion mole-
cules. Among these factors are IL-1β, tumor necrosis factor α, monocyte
chemotactic protein (MCP)-1/(CCL2), and intercellular adhesion mole-
cule 1, which stimulate and facilitate leukocyte intravasation into the
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infarct region. During permanent occlusion, neutrophil infiltration occurs
primarily during days 1–3 post-MI, while macrophage infiltration occurs
primarily during days 3–7 post-MI. During reperfusion, the kinetics and
amplitude of the inflammatory response shifts, such that bothneutrophils
and macrophages enter the tissue simultaneously as soon as reperfusion
is initiated. The transition from the inflammatory to reparative phase is
associated with the activation of pathways that turns off inflammation
and promotes ECM scar formation (Dobaczewski et al., 2010; Frantz et
al., 2009). Targets involved in inflammatory events and reparative pro-
cesseswill be central components of a successful LV remodeling biomark-
er discovery and drug target development.
3.2. MMP-9 expression in post-MI cardiac remodeling
Table 1 highlights basic science studies evaluating LV MMP-9
levels in animal models, while Table 2 highlights clinical trials exam-
ining LV MMP-9 levels in humans. MMP-9 is expressed in cardiac
myocytes, fibroblasts, vascular smooth muscle cells, endothelial
cells, neutrophils, macrophages, and fibroblasts (Coker et al., 2001;
Hasty et al., 1990; Heymans et al., 1999; Kawakami et al., 2004;
Lindsey et al., 2001, 2006b; Opdenakker et al., 2001; Porter &
Turner, 2009; van den Borne et al., 2009). MMP-9 was first described
as being able to process only collagen that was first denatured or al-
ready cleaved by collagenases such as MMP-1. Recent literature, how-
ever, has shown that MMP-9 can process full length interstitial
collagens (Egeblad & Werb, 2002; Lauer-Fields et al., 2008). Further,
MMP-9 does not require an activation cleavage step to proteolyze
substrates. Pro-MMP-9, in the presence of substrate, has enzymatic
activity without the loss of the 10 kDa pro-domain (Bannikov et al.,
2002).
MMP-9 activates several chemokines, including CXCL5, CXCL6,
and CXCL8, and contributes to the release of cell surface receptors
(e.g., tumor necrosis factor-α receptor) to alter the local microenviron-
ment (Van Den Steen et al., 2003). MMP-9 also has several inflammatory
response elements, including activator protein-1, specificity protein-1,
and NF-κB sites that makes it highly responsive to inflammatory stimuli
(Benbow & Brinckerhoff, 1997; Lindsey & Zamilpa, 2012). In the mouse,
rat, pig, rabbit, and dog models of MI, MMP-9 levels are consistently
A B C
Fig. 1. Research articles and reviews on MMP-9 published in the last decade (2001–2010). A. Total number of articles on MMP-9 published. B. Number of articles published on
MMP-9 and cardiovascular disease, including articles on the proximal effect on cardiac remodeling. C. Number of articles published on MMP-9 in other inflammatory diseases
(cancer, arthritis, and multiple sclerosis).
MMP-9 
Proximal effects on 
cardiac remodeling
Myocardial infarction
Distal effects on 
inflammatory disease
Atherosclerosis
Rheumatoid arthritis
Cancer
Inflammation
Periodontal diseaseMMP-9 inhibitors
LV rupture
Diabetes and 
aneurysms
Fig. 2. The effect of MMP-9 is broadly classified into effects proximal and distal to car-
diac remodeling. 1. Proximal effects targeted on cardiac remodeling and 2. Distal ef-
fects (non-targeted) on inflammatory diseases.
Table 1
Pre-clinical studies: A selection of articles to summarize the role of MMP-9 in cardiac
remodeling.
Reference
and year
Animal model Sex Significant findings
Heymans
et al.,
1999
MMP-9 null mice
post-MI
Male ↓ cardiac rupture
Ducharme
et al.,
2000
MMP-9 null mice
post-MI
Male ↓ collagen accumulation and
macrophage infiltration
↓ LV dimension
↑ MMP-2, MMP-13, and TIMP-1
Romanic
et al.,
2001
Rabbit post-MI Female ↑ MMP-9 within 24 h following MI
Lindsey et
al., 2005
Aging CB6F1 mice Both ↑ LV end-diastolic dimensions and
wall thickness in middle aged and old
mice.
↑ MMP-9 in old mice
Lindsey et
al., 2005
MMP-9 null mice
post-MI
Both ↑ neovascularization post-MI
Mukherjee
et al.,
2006
Gelatinase B/lacZ
transgenic mice
post-MI
Both ↑MMP-9 promoter induction at day 3,
peaks at day 7
Yan et al.,
2006
C57BL/6J mice
post-MI
Male ↑ LV rupture in middle aged mice
↑ LV remodeling and MMP-9 activity
Chiao et
al., 2011
Aging C57/BL6J
mice
Both ↑ MMP-9 and MCP-1 levels in plasma
and LV
↑ macrophage density in LV with
aging
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increased in the infarct region (Ducharme et al., 2000; Etoh et al., 2001;
Heymans et al., 1999; Lindsey et al., 2001, 2005, 2006a; Romanic et al.,
2001; Tao et al., 2004). In mouse, rabbit, and pig MI models, pharmaco-
logical MMP inhibition reduces LV dilation and preserves cardiac func-
tion (Chancey et al., 2002; Mukherjee et al., 2003; Rohde et al., 1999;
Spinale et al., 1999). Mice with targeted deletion of the MMP-9 gene
show attenuated LV dilation after experimental MI accompanied by
decreased collagen accumulation (Ducharme et al., 2000; Heymans
et al., 1999). Interestingly, however, MMP-9 deletion also stimulates
neovascularization in the post-MI infarct region (Lindsey et al.,
2006a). This suggests that MMP-9 serves both beneficial and detri-
mental roles in the post-MI response.
A striking increase in MMP-9 activity is found at days 1 to 4 in the in-
farct region, and this increase corresponds with neutrophil and macro-
phage infiltration (Ducharme et al., 2000; Heymans et al., 1999; Hudson
et al., 2006; Ramani et al., 2004; Tao et al., 2004).Mukherjee et al. demon-
strated that MMP-9 promoter transcripts with a β-galactosidase reporter
show MMP-9 promoter activity at day 3 post-MI that peaked at day 7
(Mukherjee et al., 2010). The earlier initial increase in MMP-9 protein
levels seen at day 1 post-MI is due to the release of pre-formed MMP-9
from infiltrating neutrophils, where it is stored in gelatinase granules
(Mukherjee et al., 2010).
Kelly and colleagues provided insight into the complexity of MMP-9
in terms of its having both beneficial and detrimental roles during
post-MI remodeling (Kelly et al., 2007). They found that increased
early levels of MMP-9 associated with both neutrophil numbers and
the extent of LV remodeling, indicating thatMMP-9 from the neutrophil
has an overall detrimental effect. In contrast, increased late levels of
MMP-9 associated with preservation of LV function, indicating that
MMP-9 after the initial wound healing phase may serve an overall ben-
eficial effect. The temporal profile of MMP-9, in addition to its magni-
tude, is an important consideration. Post-MI, the establishment of
new blood vessel networks is needed to supply oxygen to the highly
metabolically active infarct area (Sim et al., 2002). Of note, MMP-9
deletion enhanced neovascularization in the post-MI setting in
mice, suggesting that targeted strategies to inhibit MMP-9 early
post-MI might improve rather than impair angiogenesis (Lindsey
et al., 2006a).
Recent advances inmass spectrometry-based proteomic approaches
and new emerging technologies hold particular promise for unbiased
discovery and subsequent validation of novel biomarkers of cardiovas-
cular disease (Gerszten et al., 2011). As an example of such an approach,
Zamilpa et al. identifiedmultiple proteins that are differentially expressed
in the infarct region of MMP-9 null mice compared to wild type mice.
Among previously known in vitroMMP-9 substrates, fibronectinwas val-
idated as an in vivo MMP-9 substrate in the post-MI setting (Zamilpa et
al., 2010).
3.3. MMP-9 effects on LV rupture
LV wall rupture is one of the more serious complications, accounting
for 5 to 31% of all in-hospitalMI deaths (Figueras et al., 2000).While rup-
ture rates in humans have fallen due to the success of reperfusion, the in-
cidence of LV ruptures remains at 0.5%–1.4% (Lopez-Sendon et al., 2010).
LV ruptures are more frequent in patients with STEMI (0.9%) than pa-
tients with other acute coronary syndromes (NSTEMI, 0.17%; unstable
angina, 0.25%) (Lopez-Sendon et al., 2010). In C57BL/6J male mice, the
7 day post-MI survival rate is approximately 60%, and about one in
three deaths will occur as a result of rupture (Gao et al., 2005; Yang et
al., 2008; Zamilpa et al., 2011). Survival in female mice is about 90% at
day 7 post-MI, with about one in ten deaths occurring as a result of rup-
ture. Gender studies in 129sv mice showed that males have higher
MMP-9 activity in the infarct region associatedwith increased inflamma-
tory cell infiltration, aswell as increasedMMP-9 expression in circulating
peripheral blood mononuclear cells (Fang et al., 2010). MMP inhibition
using the CP471, 474 inhibitor significantly reduced both rupture inci-
dence and MMP-9 activity in mice, supporting a role of MMP-9 in the
pathogenesis of rupture. In humans, increased MMP-9 levels have been
detected in ruptured human ventricles (van den Bornes et al., 2009).
LV ruptures in human and mice share an association between rupture
rates and the accumulation of inflammatory cells, as well as a common
location at the border zone. LV ruptures in human andmice are disparate
in the influence of sex on rupture rates (Gao et al., 2005). In the clinical
setting, the risk of post-MI rupture is higher in females than males
(Figueras et al., 2000; Reardon et al., 1997).
Table 2
Clinical studies: A selection of articles to summarize the role of MMP-9 in cardiac
remodeling.
Reference
and year
Patient
population
(n)
Location Significant
findings
Conclusion
Blankenberg
et al.,
2003
coronary
artery disease
(1127)a
Germany MMP-9 higher at
baseline in
patients with a
subsequent fatal
CV event
MMP-9 as a
novel predictor
of future CV
mortality
Squire et al.,
2004
acute MI
(60)a
UK MMP-9 peaks at
days 1–4 post-MI
MMP-9 present
during LV
remodeling
Sundstrom
et al.,
2004
previous MI
but no heart
failure (699)a
USA Plasma MMP-9
linked to vascular
risk factors and
echocardiography
measurements in
males
MMP-9 levels
associate with
increased LV di-
astolic dimen-
sions and
increased wall
thickness
Yan et al.,
2006
symptomatic
heart failure
with reduced
ejection
fraction
(184)a
Canada and
USA
↑ MMP-9 levels
correlate with
increased LV
volumes and re-
duced LV ejection
fraction in pa-
tients with heart
failure
MMP-9 levels
associate with
cardiac
dysfunction
Hlatky et al.,
2007
acute MI or
stable angina
(199)a
USA ↑ MMP-9 in acute
MI but not stable
angina patients
MMP-9
independently
associates with
development of
an acute MI
rather than sta-
ble angina
Martos et
al., 2007
hypertensive
with diastolic
dysfunction
(86)a
Ireland ↑ MMP-9 in
diastolic heart
failure
↑ MMP-9 levels
associate with
active fibrosis
Orn S et al.,
2007
Long-term
survivors
after MI (52)a
UK and USA ↑ MMP-9 in the
acute phase after
MI, protective ef-
fect during late
LV remodeling
No relationship
between MMP-9
levels and scar
size at any time
point after MI
Van den
Borne et
al., 2009
Autopsy
samples of
post-MI rup-
tures (20)b
Netherlands ↑ MMP-9 in
ruptured LVs
↑ MMP-9 in
infarcted area
associates with
rupture
Hansson et
al., 2011
Uppsala
Longitudinal
Study of Adult
Men (ULSAM)
(1082)a
Sweden ↑ MMP-9 and
TIMP-1 in men
with CV mortality
MMP-9 and
TIMP-1 are re-
lated to CV mor-
tality risk
Kobayashi
et al.,
2011
ST elevated
ACS and
non-ST ele-
vated ACS
stable angina
patients
(266)a
Japan ↑ MMP-9 early
post-MI
MMP-9 has
higher
diagnostic
accuracy for ACS
than hs-troponin
Abbreviations: CV; cardiovascular, LV; left ventricle, ESV; end systolic volume, HF;
heart failure, MI; myocardial infarction
a Indicates that MMP-9 was analyzed by ELISA.
b Indicates MMP-9 was analyzed by zymography or immunocapture activity.
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3.4. Clinical studies: MMP-9 is a biomarker for cardiac remodeling
Blankenberg and colleagues performed the first comprehensive
clinical study that implicated MMP-9 as a novel prognostic biomarker
for individuals at increased risk for CV mortality (Blankenberg et al.,
2003). MMP-9 correlated with the acute-phase reactant proteins
IL-6, hs-CRP, and fibrinogen, indicating that MMP-9 could have its
own pathophysiological significance in cardiovascular mortality.
Squire and colleagues extended these studies to demonstrate that,
in humans, higher MMP-9 correlated with larger LV volumes and
greater dysfunction following MI (Squire et al., 2004). The Vasan
team examined patients from the Framingham Heart Study and
found that plasma MMP-9 levels associated with increased LV diastolic
dimensions and increased wall thickness (Sundstrom et al., 2004).
Hlakty and colleagues showed that circulating MMP-9 levels inde-
pendently associated with acute MI but not stable angina (Hlatky
et al., 2007). MMP-9 levels correlated with LV enlargement, lower
ventricular ejection fraction, and persistent adverse LV remodeling
in chronic systolic heart failure patients (Yan et al., 2006). Fertin et
al. examined 112 correlations among 52 different biomarkers and
LV remodeling indices. The most consistent biomarkers associated
with LV remodeling were related to ECM turnover or neurohormonal
activation. Among the biomarkers, MMP-9, collagen peptides, and
B-type natriuretic peptide were prominent biomarkers that predicted
adverse LV remodeling after MI (Fertin et al., 2012). Of note, several
polymorphisms have been evaluated within the MMP-9 gene and
have been shown to influence gene expression (B. Zhang et al., 1999).
Specifically, the C1562T allele associates with increased MMP-9 plasma
concentrations, whereas the R279Q polymorphism had no effect on
plasma levels but associated with future CV events. The 279 amino
acid where these polymorphisms occur resides in the catalytic domain
of the MMP-9 enzyme, suggesting that MMP-9 activity levels may be
higher in patients with the R279Q polymorphism (Shipley et al., 1996;
Tanner et al., 2011). Combined, these studies offer strong evidence for
a proximal role of MMP-9 in LV remodeling. In heart failure patients,
serum carboxy-terminal telopeptide of procollagen type I, carboxy-
terminal telopeptide of procollagen type I, and amino-terminal
propeptide of procollagen type III are all elevated and serve as indica-
tors of diastolic dysfunction. In these same patients, serum MMP-9
levels are elevated, suggesting increased degradation of myocardial col-
lagen (Martos et al., 2007). This particular study elegantly demonstrated
the role of MMP-9 in stimulating LV remodeling in hypertensive and
diastolic heart failure patients.
3.5. MMP-9 roles in inflammation: neutrophils,
macrophages, and lymphocytes are cell sources of MMP-9
MMP-9 is secreted by neutrophils early post-MI, and by macro-
phages, lymphocytes, and fibroblasts at later phases post-MI (Fig. 3).
In neutrophils, MMP-9 is synthesized during bone marrow granulocyte
differentiation and is released following neutrophil activation (Jonsson
et al., 2011). Fang et al. quantified MMP-9 levels in peripheral blood
mononuclear cells that were differentiated into macrophages in vitro
(Fang et al., 2007). Circulating cells isolated at day 4 after MI in
129sv mice showed increased MMP-9 levels compared to cells iso-
lated from the shammice. Peripheral bloodmononuclear cells isolat-
ed from patients with acute MI and differentiated to macrophages
also produced a higher amount of MMP-9 compared to cells isolated
from patients with stable angina or healthy controls, indicating that
macrophages are an important cellular source of plasma MMP-9
(Fang et al., 2010).
3.6. MMP-9 effects on inflammatory chemokines and cytokines
MMP-9 modulates leukocyte function through a number of
cytokine-mediated mechanisms. MMP-9 can process pro-IL-1β into
active IL-1β and can truncate IL-8 into a more active form. As both
IL-1β and IL-8 can stimulate MMP-9 degranulation from neutrophils,
providing an important positive feedback loop for neutrophil activation
and chemotaxis (Opdenakker et al., 2001).
In the post-MI setting, the overexpression of human CRP in mice re-
sults in more severe LV remodeling with increased LV dilation, a greater
extent of LV dysfunction, and more prominent cardiomyocyte hypertro-
phy and fibrosis than their littermate controls (Mano et al., 2011). The
CRP transgenic mice also display enhanced macrophage infiltration
into the infarct region, at rates that are directly proportional to increased
MCP-1 expression andMMP-9 activity (Takahashi et al., 2010). Increased
CRP, therefore, leads to increased macrophage accumulation through a
direct MMP-9 role.
3.7. MMP-9 inhibitors
It is well established that an increased expression of MMP-9 asso-
ciates with the pathological status in a wide range of inflammatory
diseases, including MI, rheumatoid arthritis, liver fibrosis, and peri-
odontal disease. A pathogenic role of MMP-9 in tissue breakdown
and remodeling during aggressive tumor growth and angiogenesis
is also established. Because of past failures with global non-specific
MMP inhibitors, the current focus in the MMP inhibitor drug discov-
ery arena is to develop inhibitors specific for particular MMPs.
The main structural requirement of an MMP inhibitor is the zinc
binding group (ZBG) that chelates the active-site zinc ion. Tandon and
Sinha applied a docking and molecular dynamics approach to study
the binding of inhibitors to the active site of MMP-9. Three categories
of zinc binding groups were chosen: 1) sulfonamide hydroxamate,
2) thioester, and 3) carboxylic moieties. Out of these three categories,
the thioester based zinc binding moiety provided the most promising
docking scores compared to the other two groups (Tandon & Sinha,
2011).
Gutierrez and colleagues demonstrated that the MMP-9 inhibitor
doxycline attenuated Trypanosoma cruzi infection induced cardiac in-
jury (Gutierrez et al., 2008). These results indicate that MMP-9 inhibi-
tion in myocarditis mollifies inflammation to increase survival in
mice (Gutierrez et al., 2008). Of interest, doxycycline is the only
FDA-approved MMP inhibitor currently on the market (Lee et al.,
2004; Zhang et al., 2012).
Pharmacological inhibition ofMMPs has been effective in limiting tis-
sue damage after MI in animal models. Villarreal et al. observed that
short-term treatment of doxycline reduced adverse LV remodeling and
improved LV function in male Sprague–Dawley rats (Villarreal et al.,
2003). MMP inhibition in humans, however, has not been as successful,
as broad-spectrum MMP inhibitors showed adverse secondary effects
on themusculoskeletal system that were linked to the non-selective na-
ture of these inhibitors (Creemers et al., 2001; Spinale, 2002).
4. MMP-9 distal effects on other inflammatory diseases (Fig. 2)
4.1. Atherosclerosis
Atherosclerosis is an inflammatory disease characterized by plaque
formation and artery wall thickening as a result of the accumulation
of lipids. Atherosclerosis mainly affects vein grafts, arterial blood ves-
sels, and also includes the accumulation ofmacrophages, low-density li-
poproteins, plasmaproteins that transport cholesterol, and triglycerides
(Ross, 1999).
Konstantino et al. have reviewed the role of MMP-9 in the patho-
physiology of atherosclerosis and plaque rupture (Konstantino et al.,
2009). While other MMPs (including MMP-1, -2, -3, -7, -8, -10, -11,
-12, and -13) have been evaluated, MMP-9 has been the most studied
MMP in atherosclerosis pathology (Konstantino et al., 2009). Despite
the number of studies that demonstrate increased MMP-9 levels
in the atherosclerotic lesion, few studies have been designed to
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determine the causal roles of MMP-9 or to explore the clinical appli-
cability of MMP-9 inhibition. Mechanistic studies in apolipoprotein E
(Apo E)-null mice model provide conflicting insight on MMP-9 roles
in plaque formation. Lutton et al. showed that after 25 weeks of a
cholesterol-rich diet, Apo E/MMP-9 double-null mice had 70% smaller
sized plaques with less collagen and macrophage content compared
with Apo E null/MMP-9+/+ mice, suggesting that MMP-9 deficiency
protects from plaque development (Luttun et al., 2004).
Conversely, Johnson et al. demonstrated a larger lesion area and in-
creased macrophage content in Apo E/ MMP-9 double-null mice com-
pared with Apo E null/MMP-9+/+ mice after 8 weeks of a high-fat
diet, indicating that MMP-9 deficiency promoted rather than impaired
atherosclerosis progression (Johnson et al., 2005). The inconsistent re-
sults could be ascribed to a variation in timing of lesion measurements,
as Johnson et al. determined the lesion size after 8 weeks of a high-fat
diet, whereas Lutton et al. assessed the lesion size after 25 weeks of a
cholesterol-rich diet. The concept that MMP function can switch from
deleterious to beneficial can be explained by a shift in substrate avail-
ability, since net MMP activity is determined by what substrates are
processed. To support this idea, Nooijer et al. demonstrated that nega-
tive effects of MMP-9 overexpression on plaque stability appear to be
more prominent in advanced atherosclerotic plaques (de Nooijer et
al., 2006). Advanced plaques showed more significant features of vul-
nerable plaque with a high incidence of intra-plaque hemorrhage (de
Nooijer et al., 2006). The overexpression of activated MMP-9 in macro-
phages induced substantial plaque disruption in advanced atherosclerotic
lesions of Apo E null mice, revealing that enhanced macrophage MMP-9
proteolytic activity can induce acute plaque disruption.MMP-9, therefore,
is a therapeutic target for stabilizing rupture-prone plaques that are in the
advanced stage. The fact thatMMP-9 andmacrophages co-exist in vulner-
able plaques highlights the role for MMP-9 in this process. Future studies
examining the temporo-spatial dynamics of MMP-9 expression during
plaque development and destabilization are required to fully understand
the significance of MMP-9 activity in atherosclerosis (Gough et al., 2006).
The cholesterol lowering drug statins (e.g. simvastatin, atorvastatin,
and pravastatin) downregulate 3-hydroxy-3-methylglutaryl coenzyme
A to improve plaque quality in atherosclerotic patients. Statins re-
duce macrophage accumulation and collagen degradation by reducing
CD40 ligand/CD40 and expression of the adhesion molecule VCAM-1
(Libby & Aikawa, 2003).
4.2. Rheumatoid arthritis
Rheumatoid arthritis is a systemic inflammatory disorder that affects
synovial joints. Patientswith rheumatoid arthritis aremore prone to ath-
erosclerosis and have increased risks for MI and stroke (Symmons &
Gabriel, 2011). The synovial fluid from patients of rheumatoid arthritis
contains increased levels of MMP-9 (Ahrens et al., 1996; Yoshihara et
al., 2000). Proteolytic degradation of articular cartilage is one of the
early features of the disease and is mediated by an increased activity of
MMP-3, -8, and -9 (Tchetverikov et al., 2003). In particular, MMP-9
cleavage of aggrecan releases multiple neo-epitopes that stimulate an
immune response to both initiate the pathogenesis and aggravate the
progression (Ram et al., 2006). MMP-9 increases in various autoimmune
diseases such as systemic lupus erythematosus, Sjogren's syndrome, sys-
temic sclerosis, multiple sclerosis, and polymyositis (Ram et al., 2006).
Therefore, MMP-9 is considered an important target for therapy in auto-
immune diseases.
4.3. Cancer
Cancer is a disease of dysregulated tissue growth. As cancer pro-
gresses, the uncontrolled growth often metastasizes and becomes in-
vasive, wherein the tumor cells spread to other locations in the body
via the lymphatic system or the bloodstream. MMPs are involved in
many cancer-related processes including invasion, metastasis, angio-
genesis, and cell proliferation (Egeblad & Werb, 2002). Although a
number of MMPs (MMP-2, -7, -9, -11, and -14) are readily detected
in most tumor types at all stages, the pattern of expression of other
MMPs (MMP-1, -3 -8, -13) varies considerably by tumor type and
stage.
Neutrophil Macrophage
ligated LAD
infarct region
Fibroblast
A) infarcted left ventricle
B) time course
7>7-32-1)syad(emiT
Cells 
involved
Myocytes
Neutrophils 
Neutrophils 
Macrophages
Fibroblasts
Endothelial cells
Macrophages
Fibroblasts
Endothelial cells
Early phase Intermediate phase Late phase
Smooth muscle cells
Smooth muscle cells
Major cell 
contributor 
of MMP-9
Fig. 3. Schematic diagram presenting infarcted left ventricle and cell sources during the different stages of MMP-9 release as result of post-MI cardiac remodeling. A. Infarcted LV at
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Roy et al. reviewed the role of specific MMPs as novel biomarkers
in different types of cancers such as breast (MMP-1, -9, -13), pancreas
(MMP-2, -7, -9), lung (MMP-1, -7, -9), bladder (MMP-2, -9), colorec-
tal (MMP-1, -2, -7, -9, -13), ovarian (2, -9, -14), prostate (MMP-2, -9)
and brain (MMP-2, -9) (Roy et al., 2009). MMP-9 is in common to
each of the above-mentioned cancers and has been proposed as an
overarching biomarker of cancer. Further, MMP-9 has been shown
to have epigenetic regulation that may provide additional biomarker
candidates.
Cancer and cardiovascular disease intersect, as treatment strategies
to fight cancer often induce cardiac dysfunction. One example of this
is the use of anthracyclines (e.g., doxorubicin) as an anti-oncogenic
therapy. Anthracyclines have known cardiotoxic side effects, including
a significant activation of MMP-9 (Goetzenich et al., 2009). The inflam-
matory component is also a strong connection between these two
diseases.
4.4. Periodontal disease
Periodontal disease is broadly classified into two subgroups: peri-
odontitis and gingivitis. Periodontitis is an inflammatory disease that
mainly affects the supporting tissues of the teeth leading to the pro-
gressive destruction of connective tissue attachments to alveolar
bone. Gingivitis is a non-destructive inflammatory disease character-
ized by an increased build-up of plaque on tooth surfaces. Longtime
untreated gingivitis progressing to periodontitis is the most destruc-
tive form of periodontal disease. MMP-8 and MMP-9 are major diag-
nostic markers that have been well described in periodontal disease
(Ramseier et al., 2009). Periodontal disease shows a multifaceted pat-
tern and progresses as a feed forward continuum of infection and
inflammatory dysregulation with subsequent bone loss. Specific bio-
markers, including MMP-8, MMP-9, IL-1β IL-6, and type I collagen
pyridinoline cross-linked telopeptide (ICTP), have been used for peri-
odontal disease identification (Ramseier et al., 2009).
4.5. Diabetes mellitus and vascular complications
Diabetes mellitus stimulates a strong the immune system re-
sponse by upregulating specific cytokines, chemokines, and leukocyte
populations to contribute to increased vascular cell apoptosis and
tissue fibrosis during plaque formation (Donath & Shoelson, 2011).
The increase in macrophage numbers associates with reduced colla-
gen content and MMP-9 overexpression in human diabetic plaques
(Cipollone et al., 2003). Furthermore, advanced glycation end prod-
ucts (the product of non-enzymatic glycation reactions stimulated
by increased circulating glucose levels) stimulate COX-2/PGES-1 ex-
pression and induce MMP-9 synthesis in macrophages (Cipollone et
al., 2003; Kadoglou & Liapis, 2004). Diabetes, therefore, exacerbates
the inflammatory response in atherosclerosis.
Abdominal aortic aneurysms (AAAs) are a chronic degenerative con-
dition associatedwith a risk of vessel wall rupture. AAAs develop due to
the progressive degradation of aortic wall elastin and collagen, and an
increase in the local production of MMP-9 has been implicated in this
process. The FDA approved MMP-9 inhibitor doxycycline reduces
MMP-9 expression in human vascular wall cell types and in AAA tissue
explants in vitro. Patients administered with doxycycline also show
suppressed MMP-9 expression in the AAA tissue (Kadoglou & Liapis,
2004; Thompson & Baxter, 1999).
5. Future directions
Based on the many proximal effects of MMP-9 on cardiac remod-
eling and the many distal effects of MMP-9 on inflammatory diseases
demonstrated in both pre-clinical and clinical studies, the further ex-
ploration of MMP-9 inhibitors is justified for the development of novel
cardiovascular agents thatmaybenefit additional inflammatory diseases.
Most currently used medications for heart failure (e.g., aldosterone an-
tagonists, diuretics, ACE inhibitors, and beta-blockers) all decrease
MMP-9 levels, indicating that screening forMMP-9 targets at early stages
may help in the decision making process for cardiovascular drug discov-
ery. While non-specific MMP inhibitor strategies have not proven useful
(Peterson, 2004), a specific inhibitor strategy that targets MMP-9 may
prove effective. Several groups, however, are making headway in the
MMP specific inhibitor arena (Johnson et al., 2011; Robichaud et al.,
2011).
There are several investigation streams that remain to be ex-
plored, before the potential of MMP-9 to serve as a diagnostic marker
can be fully realized. These include:
a. MMP-9 specificity and selectivity as a biomarker and comparative
advantages over current gold standard biomarkers such as BNP,
N-terminal pro-BNP, troponin, or CRP need to be determined.
b. The associations betweenMMP-9 levels and common risk factors for
cardiovascular disease, including obesity, hypertension, smoking, di-
abetes, and dyslipidemia need to be dissected.
c. Spatial and temporal MMP-9 patterns during the cardiac remodel-
ing continuum and during other inflammatory disease (e.g. cancer,
arthritis, and periodontal disease) are needed.
d. The spatial and temporal patterns of MMP-9, compared with the
patterns of other MMPs in cardiac remodeling and inflammatory
diseases, need to be determined.
e. Standardized procedures and practices are needed for the pre-
analytical, analytical, and post-analytical platforms to evaluate
MMP-9 performance.
6. Conclusions
Current pre-clinical and clinical documentation strongly support
MMP-9 as a panel member in the biomarker list to diagnose or treat
the pathophysiology of post-MI ventricular remodeling and congestive
heart failure. Immune cells such as neutrophils or macrophages modify
many processes in theMI response, and future research focused on bio-
chemical and structural approaches to examine the ECMwill likely pro-
vide new information on the remodeling process. Based on the evidence
provided, further prospective studies are required to assess the prog-
nostic value of MMP-9 for post-MI remodeling, particularly in compar-
ison with traditional markers.
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